Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab deruxtecan - AstraZeneca/Daiichi Sankyo

Drug Profile

Trastuzumab deruxtecan - AstraZeneca/Daiichi Sankyo

Alternative Names: DS 8201; DS 8201a; ENHERTU; Enhertu; fam-trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki; T-DXd; VRN-101099

Latest Information Update: 06 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Company; Medica Scientia Innovation Research; Seagen
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer
  • Registered Solid tumours
  • Phase II Adenocarcinoma; Biliary cancer; Colorectal cancer; Uterine cancer
  • Phase I/II Urogenital cancer

Most Recent Events

  • 02 Jun 2024 Updated efficacy and adverse events data form the phase III DESTINY-Breast03 trial in Breast cancer released by Daiichi Sankyo
  • 02 Jun 2024 Updated efficacy and adverse events data from the phase Ib/II DESTINY-Breast07 trial in Breast cancer released by Daiichi Sankyo
  • 02 Jun 2024 Updated efficacy and adverse events from phase III DESTINY-Breast06 trial for Breast cancer data released by Daiichi Sankyo
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top